Forvis Mazars Wealth Advisors LLC Has $5.87 Million Stock Holdings in Stryker Corporation $SYK

Forvis Mazars Wealth Advisors LLC lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 0.9% in the second quarter, according to its most recent filing with the SEC. The firm owned 14,838 shares of the medical technology company’s stock after selling 128 shares during the period. Forvis Mazars Wealth Advisors LLC’s holdings in Stryker were worth $5,870,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mar Vista Investment Partners LLC grew its holdings in shares of Stryker by 10.2% in the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after buying an additional 8,353 shares during the period. United Services Automobile Association acquired a new position in shares of Stryker in the 1st quarter valued at $2,857,000. AXS Investments LLC grew its holdings in shares of Stryker by 13.7% in the 1st quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock valued at $3,286,000 after buying an additional 1,062 shares during the period. Park Edge Advisors LLC acquired a new position in shares of Stryker in the 2nd quarter valued at $679,000. Finally, Hendley & Co. Inc. grew its holdings in shares of Stryker by 60.3% in the 2nd quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock valued at $5,546,000 after buying an additional 5,274 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Redburn Partners set a $420.00 price target on shares of Stryker in a report on Thursday, September 18th. Needham & Company LLC boosted their price target on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a report on Wednesday, October 8th. BTIG Research boosted their price objective on shares of Stryker from $407.00 to $408.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Finally, UBS Group set a $408.00 price objective on shares of Stryker in a research report on Monday, October 13th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $431.76.

Insider Activity

In other news, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Trading Up 1.5%

SYK opened at $374.67 on Friday. The firm’s fifty day simple moving average is $379.40 and its 200 day simple moving average is $378.77. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock has a market capitalization of $143.24 billion, a P/E ratio of 49.63, a P/E/G ratio of 2.70 and a beta of 0.94.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. During the same period in the previous year, the firm posted $2.81 EPS. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s payout ratio is 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.